Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Operating revenue increased to JPY1.4bn (+39.1% YoY), with an operating loss of JPY154mn and a recurring loss of JPY278mn.</li><li>Royalty income from four launched products and global expansion of tegoprazan generated JPY998mn (+36.3% YoY) in 1H FY12/24.</li><li>Total operating expenses rose to JPY1.6bn (+50.9% YoY), including R&D expenses of JPY833mn (+38.0% YoY) and SG&A expenses of JPY506mn (+62.1% YoY).</li></ul>

Operating revenue increased to JPY1.4bn (+39.1% YoY), with an operating loss of JPY154mn and a recurring loss of JPY278mn.Royalty income from four launched products and global expansion of tegoprazan generated JPY998mn (+36.3% YoY) in 1H FY12/24.Total operating expenses rose to JPY1.6bn (+50.9% YoY), including R&D expenses of JPY833mn (+38.0% YoY) and SG&A expenses of JPY506mn (+62.1% YoY).

Raqualia Pharma (4579 JP): 1H FY12/24 flash update

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Key Drivers<ul>
<li>Stable income of ¥ 0.5b - ¥1b from Animal Healthcare segment</li>
<li>Pharma segment – royalty income from Tegoprazan (South K approved June 2018) and Ziprasidone (PhIII, approval expected in FY20e)</li>
<li>Potential upfront/milestones from the partnered assets and/or or out-licensing activity but timeline uncertain</li>
</ul>Valuations<ul><li>Our explicit revenue projection until 2030e, which includes probability adjusted royalty from tegoprazan (PoS 100%), Ziprasidone (PoS 90%) and tamibarotene (PoS 30%) yields DCF based fair value of ¥ 800 / share. We add acquisition premium of ~50% to arrive at target price of ¥1,200 / share</li></ul>

Key Drivers
Stable income of ¥ 0.5b - ¥1b from Animal Healthcare segment
Pharma segment – royalty income from Tegoprazan (South K approved June 2018) and Ziprasidone (PhIII, approval expected in FY20e)
Potential upfront/milestones from the partnered assets and/or or out-licensing activity but timeline uncertain
ValuationsOur explicit revenue projection until 2030e, which includes probability adjusted royalty from tegoprazan (PoS 100%), Ziprasidone (PoS 90%) and tamibarotene (PoS 30%) yields DCF based fair value of ¥ 800 / share. We add acquisition premium of ~50% to arrive at target price of ¥1,200 / share

Japan

RaQualia Pharma, Inc. is a pharmaceutical company. The Company develops compounds for patient studies and sells drugs to pharmaceutical manufacturers. RaQualia also provides research on remedies in gastrointestinal, liver diseases, and pain in general areas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Raqualia Pharma (4579 JP)